Researchers linked higher plasma TMAO to prevalent atrial fibrillation in 5,090 people and found that TMAO or choline supplementation accelerated AF onset, progression, atrial remodeling, and electrical dysfunction in mice. Inhibiting gut microbial TMA production lowered circulating TMAO and delayed AF in mice, identifying a potential therapeutic pathway that now requires human testing.